Abstract
Introduction: To reduce cardiovascular risk associated with hypertension, the majority of patients require at least two drugs to control their blood pressure (BP), and many require three or more. Methods: An open-label extension of a 10-week double-blind study assessed the long-term efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide (OLM/AML/HCTZ) triple combination treatment in 2,509 patients with Grade 2-3 hypertension. After 8 weeks of single-blind OLM/AML/HCTZ 20/5/12.5 mg treatment, patients at BP goal [seated systolic/diastolic BP (SeSBP/SeDBP)
Original language | English |
---|---|
Pages (from-to) | 561-574 |
Number of pages | 14 |
Journal | Advances in Therapy |
Volume | 31 |
Issue number | 5 |
DOIs | |
Publication status | Published - 2014 |
Keywords
- Cardiology
- Hypertension
- Olmesartan/amlodipine/hydrochlorothiazide
- Open-label
- Seated diastolic blood pressure
- Seated systolic blood pressure
- Triple combination
ASJC Scopus subject areas
- Medicine(all)
- Pharmacology (medical)